US · PPCB
Propanc Biopharma, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Camberwell, VIC 3124
- Website
- propanc.com
Price · as of 2025-06-30
$0.10
Market cap 3.06M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | $49,999,998,976.00 | ||||
| 2014 | $20,750,000,128.00 | ||||
| 2015 | $9,125,000,192.00 | ||||
| 2016 | $4,075,000,064.00 | ||||
| 2017 | $322,500,000.00 | ||||
| 2018 | $82,100,000.00 | ||||
| 2019 | $2,100,000.00 | ||||
| 2020 | $3,600.00 | ||||
| 2021 | $63.20 | ||||
| 2022 | $4.60 | ||||
| 2023 | $0.07 | ||||
| 2024 | $0.00 | ||||
| 2025 | $2.15 |
AI valuation
Our deep-learning model estimates Propanc Biopharma, Inc.'s (PPCB) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $0.10
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| PPCB | Propanc Biopharma, Inc. | $0.10 | 3.06M | — | — | — | — | -0.14 | 0.61 | — | -0.18 | — | 0.61 | 0.00% | — | — | -1163.67% | -897.14% | -598.08% | 0.12 | -101.60 | 1.50 | 0.00 | -0.03 | -9876.00% | — | -5667.00% | -4.75% | -0.07 | -6.35% | 0.00% | 0.00% | 0.00% | -0.18 | -25.29 | — | -17.52 |
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc., a biopharmaceutical company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
- CEO
- James Nathanielsz
- Employees
- 1
- Beta
- 3.50
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $0.10) − 1 = — (DCF, example).